Work

MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw378.56

Authors: S. Domchek, Y.-J. Bang, G. Coukos, K. Kobayashi, N. Baker, E. McMurtry, W. Song, B. Kaufman

Institutions: Abramson Cancer Center, Seoul National University, Centre Hospitalier Universitaire Vaudois, Ludwig Cancer Research, AstraZeneca (United States), AstraZeneca (United Kingdom), Sheba Medical Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2586645609

FWCI: 0.773

Cites:

Cited by: 10

Related to: 10